Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing

Lung Cancer

Volumn 77, Issue 1, 2012, Pages 31-37

  Basseres, Daniela S ^a,e   D'Alò, Francesco ^a   Yeap, Beow Y ^b   Löwenberg, Ester C ^a   Gonzalez, David A ^a   Yasuda, Hiroyuki ^a   Dayaram, Tajhal ^a   Kocher, Olivier N ^a   Godleski, John J ^c   Richards, William G ^c   Meyerson, Matthew ^a   Kobayashi, Susumu ^a   Tenen, Daniel G ^a   Halmos, Balázs ^d   Costa, Daniel B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adenocarcinoma; Downregulation; Epigenetic; Foxa2; Lung cancer; Methylation; Mutation; Non small cell lung cancer; Prognosis; Transcription factors

Indexed keywords

CELL DNA; DINUCLEOTIDE; HEPATOCYTE NUCLEAR FACTOR 3BETA; MESSENGER RNA;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CHROMOSOME DELETION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; FEMALE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; GENE SILENCING; GENETIC EPIGENESIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TRANSCRIPTION REGULATION;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; DOWN-REGULATION; EPIGENESIS, GENETIC; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE NUCLEAR FACTOR 3-BETA; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC;

EID: 84861738981     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.01.011     Document Type: Article

References (28)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Maeda Y., Dave V., Whitsett J.A. Transcriptional control of lung morphogenesis. Physiol Rev 2007, 87(1):219-244.
3. Halmos B., Huettner C.S., Kocher O., Ferenczi K., Karp D.D., Tenen D.G. Down-regulation and antiproliferative role of C/EBPalpha in lung cancer. Cancer Res 2002, 62(2):528-534.
4. Costa D.B., Li S., Kocher O., Feins R.H., Keller S.M., Schiller J.H., et al. Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590. Lung Cancer 2007, 56(1):97-103.
5. Koschmieder S., Halmos B., Levantini E., Tenen D.G. Dysregulation of the C/EBPalpha differentiation pathway in human cancer. J Clin Oncol 2009, 27(4):619-628.
6. Tada Y., Brena R.M., Hackanson B., Morrison C., Otterson G.A., Plass C. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. J Natl Cancer Inst 2006, 98(6):396-406.
7. Weir B.A., Woo M.S., Getz G., Perner S., Ding L., Beroukhim R., et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007, 450(7171):893-898.
8. Barletta J.A., Perner S., Iafrate A.J., Yeap B.Y., Weir B.A., Johnson L.A., et al. Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med 2009, 13(8B):1977-1986.
9. Kwei K.A., Kim Y.H., Girard L., Kao J., Pacyna-Gengelbach M., Salari K., et al. Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene 2008, 27(25):3635-3640.
10. Bass A.J., Watanabe H., Mermel C.H., Yu S., Perner S., Verhaak R.G., et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009, 41(11):1238-1242.
11. Wilbertz T., Wagner P., Petersen K., Stiedl A.C., Scheble V.J., Maier S., et al. SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol 2011, 24(7):944-953.
12. Lai E., Clark K.L., Burley S.K., Darnell J.E. Hepatocyte nuclear factor 3/fork head or "winged helix" proteins: a family of transcription factors of diverse biologic function. Proc Natl Acad Sci USA 1993, 90(22):10421-10423.
13. Ang S.L., Rossant J. HNF-3 beta is essential for node and notochord formation in mouse development. Cell 1994, 78(4):561-574.
14. Monaghan A.P., Kaestner K.H., Grau E., Schutz G. Postimplantation expression patterns indicate a role for the mouse forkhead/HNF-3 alpha, beta and gamma genes in determination of the definitive endoderm, chordamesoderm and neuroectoderm. Development 1993, 119(3):567-578.
15. Wan H., Xu Y., Ikegami M., Stahlman M.T., Kaestner K.H., Ang S.L., et al. Foxa2 is required for transition to air breathing at birth. Proc Natl Acad Sci USA 2004, 101(40):14449-14454.
16. Wan H., Dingle S., Xu Y., Besnard V., Kaestner K.H., Ang S.L., et al. Compensatory roles of Foxa1 and Foxa2 during lung morphogenesis. J Biol Chem 2005, 280(14):13809-13816.
17. Stahlman M.T., Gray M.E., Whitsett J.A. Temporal-spatial distribution of hepatocyte nuclear factor-3beta in developing human lung and other foregut derivatives. J Histochem Cytochem 1998, 46(8):955-962.
18. Bohinski R.J., Di Lauro R., Whitsett J.A. The lung-specific surfactant protein B gene promoter is a target for thyroid transcription factor 1 and hepatocyte nuclear factor 3, indicating common factors for organ-specific gene expression along the foregut axis. Mol Cell Biol 1994, 14(9):5671-5681.
19. Ikeda K., Shaw-White J.R., Wert S.E., Whitsett J.A. Hepatocyte nuclear factor 3 activates transcription of thyroid transcription factor 1 in respiratory epithelial cells. Mol Cell Biol 1996, 16(7):3626-3636.
20. Halmos B., Basseres D.S., Monti S., D'Alo F., Dayaram T., Ferenczi K., et al. A transcriptional profiling study of CCAAT/enhancer binding protein targets identifies hepatocyte nuclear factor 3 beta as a novel tumor suppressor in lung cancer. Cancer Res 2004, 64(12):4137-4147.
21. Costa D.B., Halmos B., Kumar A., Schumer S.T., Huberman M.S., Boggon T.J., et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 2007, 4(10):1669-1679.
22. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352(8):786-792.
23. Kwiatkowski D.J., Harpole D.H., Godleski J., Herndon J.E., Shieh D.B., Richards W., et al. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol 1998, 16(7):2468-2477.
24. Costa D.B., Dayaram T., D'Alo F., Wouters B.J., Tenen D.G., Meyerson M., et al. C/EBP alpha mutations in lung cancer. Lung Cancer 2006, 53(2):253-254.
25. Rauch T.A., Zhong X., Wu X., Wang M., Kernstine K.H., Wang Z., et al. High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci USA 2008, 105(1):252-257.
26. Sholl L.M., Barletta J.A., Yeap B.Y., Chirieac L.R., Hornick J.L. Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am J Surg Pathol 2010, 34(8):1193-1198.
27. Tang Y., Shu G., Yuan X., Jing N., Song J. FOXA2 functions as a suppressor of tumor metastasis by inhibition of epithelial-to-mesenchymal transition in human lung cancers. Cell Res 2011, 21(2):316-326.
28. Huang G., Eisenberg R., Yan M., Monti S., Lawrence E., Fu P., et al. 15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer. Cancer Res 2008, 68(13):5040-5048.